Rocket Lab SEC Filings

Director Merline Saintil acquired 2,482 shares through a restricted stock unit (RSU) grant. This transaction is neutral as it represents standard director compensation rather than an open market purchase.

Director Alexander R. Slusky acquired 2,482 shares of common stock through a restricted stock unit (RSU) grant. This is a neutral transaction as it represents compensation rather than an open market purchase.

Rocket Lab held its 2026 Annual Meeting of Stockholders on May 20, 2026. Shareholders voted on four proposals, including the election of a Class II director, ratification of Deloitte & Touche LLP as independent auditors, advisory approval of executive compensation, and approval of a subsidiary merger to eliminate certain pass-through voting provisions.

This 424B5 filing is a prospectus supplement for an equity distribution agreement allowing Rocket Lab Corporation to sell common stock over time. The offering includes 'at the market' sales and various forward sale transactions, including initially priced and collared forward transactions. The proceeds are intended for future growth, acquisitions, and general working capital.

Rocket Lab entered into an Equity Distribution Agreement with multiple sales agents to offer and sell up to $3,000,000,000 of common stock. The agreement includes provisions for both standard sales and complex forward sale agreements, including 'Initially Priced' and 'Collared' forward transactions. Proceeds will be received upon future physical settlement or prepayment dates as specified by the company.

Director Alexander R. Slusky executed multiple sales of common stock and one charitable gift. The overall signal is bearish due to the significant liquidation of indirect holdings.

This Form 144 filing notifies the SEC of a proposed sale of common stock by Rocket Lab Director Alexander R. Slusky. The sale involves 100,000 shares with an approximate aggregate market value of $11,807,000. This disclosure is relevant to investors as it tracks insider selling activity and potential liquidity events from large shareholders.

The document serves as a notice and instructional guide for the 2026 Annual Shareholders' Meeting. It provides detailed voting instructions across various brokerage platforms for shareholders of record as of March 30, 2026.

This 424B7 filing is a prospectus supplement for the resale of up to 2,277,002 shares of common stock by selling stockholders. These shares were issued on April 14, 2026, as partial consideration for the acquisition of Mynaric AG. The filing is relevant to investors as it enables the primary parties in the acquisition to liquidate their equity positions.

Rocket Lab filed a prospectus supplement to enable the resale of up to 2,277,002 shares of common stock. These shares were issued on April 14, 2026, as part of a private placement related to the acquisition of Mynaric AG. This filing is a requirement under the existing Stock Purchase Agreement.